Summary Review, NDA 204630 ProvayBlue (methylene blue) – ‘marketed unapproved drug’ status before approval (2016)

Government Record · U.S. Food and Drug Administration, Center for Drug Evaluation and Research (Division Director Summary Review, Reference ID 3913899) · April 7, 2016

U.S. Food et al., 2016-04-07: FDA's summary review states that before this approval no therapeutic was approved for acquired methemoglobinemia, and that methylene blue was a marketed but unapproved drug used for decades; the application rested on a retrospective chart review (PVP-2013001) and literature cases showing bioequivalence to Methylene Blue USP 1%.

There are no therapeutics approved for treatment of acquired methemoglobinemia. However, methylene blue is a marketed unapproved drug that has been used for many decades to treat patients with acquired methemoglobinemia.

printed p.4 (PDF p.5)

U.S. Food et al., 2016-04-07: FDA's summary review states that before this approval no therapeutic was approved for acquired methemoglobinemia, and that methylene blue was a marketed but unapproved drug used for decades; the application rested on a retrospective chart review (PVP-2013001) and literature cases showing bioequivalence to Methylene Blue USP 1%. C7 – prior unapproved-marketed-drug status, NDA 204630 summary review. Also on the same page: 'Methylene Blue is a marketed unapproved drug currently used for treatment of acquired methemoglobinemia' (section 2 Background, printed p.5). Efficacy basis: 3 subjects in Protocol PVP-2013001 plus 3 literature cases with Methylene Blue USP 1%; 6/6 had >=50% methemoglobin reduction within 1 hour. PDUFA goal date 9 April 2016. Fetch route: curl -A 'Mozilla/5.0' then pdftotext -layout. Also filed as MTP-13, MTP-33 (claims C2, C5, C7). Study type: regulatory record.